GlassScriptPhysician profile
Neehar D Parikh
NPI 1669655478
$101,216.04
in general payments reported to CMS, 2019-2025
15 companies · $7,503 in 2025
The $7,503 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $12K · 2021: $14K · 2022: $14K · 2023: $14K · 2024: $6,342 · 2025: $7,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $1,024 · Honoraria: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,117.50 |
| Food and Beverage | $1,024.29 |
| Honoraria | $740.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $29,892.12 | 2019-2024 | Cabometyx |
| Eisai INC. | $14,513.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $10,725.00 | 2019-2020 | |
| Genentech USA, INC. | $8,712.67 | 2020-2024 | Tecentriq |
| Exact Sciences Corporation | $6,485.21 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $5,578.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $5,365.50 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $4,160.78 | 2022-2025 | Utaswako Afp-L3 |
| Genentech, INC. | $3,745.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $3,735.98 | 2024 | Imfinzi |
| Sirtex Medical INC | $3,253.51 | 2025 | Sir-Spheres Microspheres |
| Bayer Healthcare Pharmaceuticals INC. | $2,153.37 | 2019-2020 | |
| Eli Lilly and Company | $1,593.24 | 2021 | |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $1,202.23 | 2019 | |
| Astellas Pharma US INC | $99.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neehar Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.